DelveInsight’s, “Smoking Cessation Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Smoking Cessation pipeline landscape. It covers the Smoking Cessation Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Smoking Cessation Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the Smoking Cessation Pipeline? Click here to explore the therapies and trials making headlines @ Smoking Cessation Pipeline Outlook Report
Key Takeaways from the Smoking Cessation Pipeline Report
- On 02 October 2025, Achieve Life Sciences conducted a study about safety assessment of long-term 3 mg cytisinicline three times daily (TID) exposure for 52 weeks is the main purpose of this study, conducted in the United States.
- On 01 October 2025, M.D. Anderson Cancer Center announced an investigational study about Varenicline and the nicotine patch are both FDA approved and commercially available to help people stop smoking.
- DelveInsight’s Smoking Cessation Pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Smoking Cessation treatment.
- The leading Smoking Cessation Companies such as Poxel, Achieve Life Sciences, Embera Pharmaceuticals, Camino Pharma, NFL Biosciences, Astraea, Antidote Therapeutics, Mydecine Innovations and others.
- Promising Smoking Cessation Therapies such as Meclizine, Centanafadine, Varenicline, Bupropion, CQSS2, Nicotine Patches, Cytisinicline, EVT 302, Nalmefene and others.
Want to know which companies are leading innovation in Smoking Cessation? Dive into the full pipeline insights @ Smoking Cessation Clinical Trials Assessment
The Smoking Cessation Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Smoking Cessation Pipeline Report also highlights the unmet needs with respect to the Smoking Cessation.
Smoking Cessation Overview
Smoking cessation refers to the process of quitting smoking, a significant health decision that can drastically improve overall well-being and reduce the risk of numerous diseases, including cardiovascular diseases, chronic obstructive pulmonary disease (COPD), and lung cancer. Despite the addictive nature of nicotine, many individuals attempt to quit due to growing awareness of the associated health risks. Governments and health organizations globally promote smoking cessation through public health campaigns, providing resources such as quitlines, counseling, and pharmacological aids to increase the chances of success.
Smoking Cessation Emerging Drugs
- Cytisinicline: Achieve Life Sciences
Cytisinicline (cytisine) is an oral, plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. Cytisinicline dual-acting MOA specifically targets the α4β2 nicotine receptor. Its partial agonist/partial antagonist activity is believed to help reduce nicotine cravings, withdrawal symptoms, and reward and satisfaction associated with smoking. The α4β2 nicotinic receptor is a well-understood target in addiction. When nicotine binds to this receptor, it causes dopamine to be released, reinforcing the dopamine reward system. This receptor has been implicated in the development and maintenance of nicotine dependence. Cytisinicline is believed to act as a partial agonist, preventing nicotine from binding and releasing dopamine. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with smoking cessation
- EMB-001: Embera Pharmaceuticals
EMB-001 is a patented combination product that includes two FDA-approved medications: metyrapone, a cortisol synthesis inhibitor, and oxazepam, a benzodiazepine. This approach is based on the understanding of how stress influences addiction. The main objective of addiction treatment is to achieve long-term abstinence while reducing the likelihood of relapse. Relapses can be triggered by three primary factors: stress (such as family conflicts), cues (like seeing drug paraphernalia), and drug exposure (even minimal contact can reactivate addiction). These triggers often provoke stress responses, leading to the theory that managing these pathways may help mitigate all three relapse causes. By combining these two medications, which affect different elements of the stress response at lower doses, EMB-001 may offer greater effectiveness than either drug alone. A therapy that effectively tackles these barriers and fosters long-term abstinence and recovery would be a major breakthrough in treating a wide range of addictions. The drug is in Phase II stage of development.
- SBP-9330: Camino Pharma, LLC
SBP-9330, a small molecule that was discovered by Cosford and his team at Sanford Burnham Prebys. SBP-9330 targets a receptor called metabotropic glutamate receptor 2 (mGlu2), which leads to reduced levels of glutamate—a neurotransmitter linked to nicotine addiction and relapse behavior. SBP-9330 is a positive allosteric modulator (PAM) of mGlu2 and thus represents a new class of drugs for treating substance use disorders. Currently, the drug is in the Phase I stage of its development for the treatment of Smoking Cessation disorders.
If you’re tracking ongoing Smoking Cessation Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Smoking Cessation Treatment Drugs
The Smoking Cessation Pipeline report provides insights into:-
- The report provides detailed insights about companies that are developing therapies for the treatment of Smoking Cessation with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Smoking Cessation Treatment.
- Smoking Cessation Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Smoking Cessation Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Smoking Cessation market.
Smoking Cessation Companies
Poxel, Achieve Life Sciences, Embera Pharmaceuticals, Camino Pharma, NFL Biosciences, Astraea, Antidote Therapeutics, Mydecine Innovations and others.
Smoking Cessation Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Smoking Cessation Products have been categorized under various Molecule types such as,
- Oligonucleotide
- Peptide
- Small molecule
From emerging drug candidates to competitive intelligence, the Smoking Cessation Pipeline Report covers it all – check it out now @ Smoking Cessation Market Drivers and Barriers, and Future Perspectives
Scope of the Smoking Cessation Pipeline Report
- Coverage- Global
- Smoking Cessation Companies- Poxel, Achieve Life Sciences, Embera Pharmaceuticals, Camino Pharma, NFL Biosciences, Astraea, Antidote Therapeutics, Mydecine Innovations and others.
- Smoking Cessation Therapies- Meclizine, Centanafadine, Varenicline, Bupropion, CQSS2, Nicotine Patches, Cytisinicline, EVT 302, Nalmefene and others.
- Smoking Cessation Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Smoking Cessation Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research – discover what’s next for the Smoking Cessation Treatment landscape in this detailed analysis @ Smoking Cessation Emerging Drugs and Major Players
Table of Contents
- Introduction
- Executive Summary
- Smoking Cessation: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Smoking Cessation– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase II/III)
- EMB-001: Embera NeuroTherapeutics, Inc.
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Drug name : Company name
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- SBP 9330: Camino Pharma
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name : Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Smoking Cessation Key Companies
- Smoking Cessation Key Products
- Smoking Cessation- Unmet Needs
- Smoking Cessation- Market Drivers and Barriers
- Smoking Cessation- Future Perspectives and Conclusion
- Smoking Cessation Analyst Views
- Smoking Cessation Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/smoking-cessation-pipeline-insight